CN102516124B - 具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯及制备方法 - Google Patents
具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯及制备方法 Download PDFInfo
- Publication number
- CN102516124B CN102516124B CN201110357871.5A CN201110357871A CN102516124B CN 102516124 B CN102516124 B CN 102516124B CN 201110357871 A CN201110357871 A CN 201110357871A CN 102516124 B CN102516124 B CN 102516124B
- Authority
- CN
- China
- Prior art keywords
- formula
- hydroxamic acid
- acid
- organic solvent
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000002253 acid Substances 0.000 title claims abstract description 28
- 150000002148 esters Chemical class 0.000 title abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 7
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 title abstract 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 18
- 239000003960 organic solvent Substances 0.000 claims abstract description 11
- 102000003964 Histone deacetylase Human genes 0.000 claims abstract description 8
- 108090000353 Histone deacetylase Proteins 0.000 claims abstract description 8
- 229940002612 prodrug Drugs 0.000 claims abstract description 8
- 239000000651 prodrug Substances 0.000 claims abstract description 8
- -1 dicarboxylic acid di-ester Chemical class 0.000 claims abstract description 7
- 239000003112 inhibitor Substances 0.000 claims abstract description 6
- 239000002608 ionic liquid Substances 0.000 claims abstract description 6
- 230000000694 effects Effects 0.000 claims abstract description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 11
- 229960000237 vorinostat Drugs 0.000 claims description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 4
- KYCQOKLOSUBEJK-UHFFFAOYSA-M 1-butyl-3-methylimidazol-3-ium;bromide Chemical compound [Br-].CCCCN1C=C[N+](C)=C1 KYCQOKLOSUBEJK-UHFFFAOYSA-M 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 15
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 230000035699 permeability Effects 0.000 abstract description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 abstract 2
- 241001597008 Nomeidae Species 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 230000002700 inhibitory effect on cancer Effects 0.000 abstract 1
- 238000003756 stirring Methods 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 5
- OHRURASPPZQGQM-UHFFFAOYSA-N romidepsin Natural products O1C(=O)C(C(C)C)NC(=O)C(=CC)NC(=O)C2CSSCCC=CC1CC(=O)NC(C(C)C)C(=O)N2 OHRURASPPZQGQM-UHFFFAOYSA-N 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 201000005962 mycosis fungoides Diseases 0.000 description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 108010091666 romidepsin Proteins 0.000 description 3
- IQQRAVYLUAZUGX-UHFFFAOYSA-N 1-butyl-3-methylimidazolium Chemical compound CCCCN1C=C[N+](C)=C1 IQQRAVYLUAZUGX-UHFFFAOYSA-N 0.000 description 2
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 201000006966 adult T-cell leukemia Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 2
- 229960005184 panobinostat Drugs 0.000 description 2
- FWZRWHZDXBDTFK-ZHACJKMWSA-N panobinostat Chemical compound CC1=NC2=CC=C[CH]C2=C1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FWZRWHZDXBDTFK-ZHACJKMWSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229960003452 romidepsin Drugs 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- QGZCUOLOTMJILH-UHFFFAOYSA-N 2h-tetrazol-2-ium;bromide Chemical compound [Br-].C1=N[NH+]=NN1 QGZCUOLOTMJILH-UHFFFAOYSA-N 0.000 description 1
- MAUCONCHVWBMHK-UHFFFAOYSA-N 3-[(dimethylamino)methyl]-N-[2-[4-[(hydroxyamino)-oxomethyl]phenoxy]ethyl]-2-benzofurancarboxamide Chemical compound O1C2=CC=CC=C2C(CN(C)C)=C1C(=O)NCCOC1=CC=C(C(=O)NO)C=C1 MAUCONCHVWBMHK-UHFFFAOYSA-N 0.000 description 1
- PLIVFNIUGLLCEK-UHFFFAOYSA-N 7-[4-(3-ethynylanilino)-7-methoxyquinazolin-6-yl]oxy-n-hydroxyheptanamide Chemical compound C=12C=C(OCCCCCCC(=O)NO)C(OC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 PLIVFNIUGLLCEK-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229950008805 abexinostat Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940011083 istodax Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- MUTBJZVSRNUIHA-UHFFFAOYSA-N n-hydroxy-2-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 MUTBJZVSRNUIHA-UHFFFAOYSA-N 0.000 description 1
- QRGHOAATPOLDPF-VQFNDLOPSA-N nanatinostat Chemical compound N1=CC(C(=O)NO)=CN=C1N1C[C@@H]([C@@H]2NCC=3N=C4C=CC(F)=CC4=CC=3)[C@@H]2C1 QRGHOAATPOLDPF-VQFNDLOPSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 229940061261 zolinza Drugs 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/54—Improvements relating to the production of bulk chemicals using solvents, e.g. supercritical solvents or ionic liquids
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及具有抗肿瘤作用的异羟肟酸类组蛋白去乙酰化酶(HDAC)抑制剂的二元羧酸
Description
技术领域
本发明涉及一类具有抗肿瘤作用的异羟肟酸的二元羧酸酯衍生物及制备方法,具体地说,涉及一类具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯及其制备方法。
背景技术
针对现有化学治疗药物存在的选择性较低、毒性较大的不足,研究寻找高效、低毒、肿瘤细胞特异性的抗肿瘤药物对于癌症的治疗意义重大。
组蛋白去乙酰化酶抑制剂(histone deacetyltransferaseinhibitors,HDACis)是近年来发展的一类新型抗肿瘤药物。已经上市的HDACi有伏立诺他(Vorinostat,SAHA,1)和罗米地辛(Romidepsin,FK-228,13),它们分别于2006年10月和2009年11月获美国FDA批准分别以商品名Zolinza和IStodax上市,用于治疗皮肤T细胞淋巴瘤(CTCL)。正在进行临床研究的异羟肟酸类HDACis包括:伏立诺他(Vorinostat,SAHA,1)Novartis公司的Panobinostat(2,LBH589,III期临床)、Topotarget的Belinostat(3,PXD101,III期临床)、Italfarmaco的ITF-2357(4,II期临床)、S*BIO的SB-939(5,I期临床)、Pharmacyclics的PCI-24781(6,I期临床)、J&J的JNJ-16241199(7,I期临床)、CUDC-101(8,I期临床)和CHR-3996(9,I期临床)。
发明内容
本发明的目的在于克服组蛋白去乙酰化酶抑制剂(HDACis)的不足,提供具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯前药衍生物。与异羟肟酸类组蛋白去乙酰化酶抑制剂原药相比,该类衍生物细胞渗透性明显提高,可用于抑制HDAC,用于选择性诱导瘤性细胞末端分化,导致细胞生长停滞和、凋亡,从而达到抑制此类细胞增殖的目的。
本发明所要制备的异羟肟酸类组蛋白去乙酰化酶抑制剂的二元羧酸双(异羟肟酸)酯衍生物,其结构如式I所示:
式I中,RCONHOH为异羟肟酸1-9;
Y为:(CH2)n(n等于2,3,4,5,6)等。
本发明所提供的制备式所示化合物的方法,其主要步骤是:由异羟肟酸类RCONHOH(其结构如式II所示)与二元羧酸HOCOYCOOH(其结构如式III所示)于溶媒(有机溶剂或离子液体)中在羰基二咪唑(CDI)作用下,于0-200℃反应,制得目标物(式I所示化合物)。
RCONHOH HOCOYCOOH
II III
式III中,Y的定义与前文所述相同。
具体实施方式
在本发明一个优选的技术方案中,二元羧酸双(异羟肟酸)酯衍生物(I)代表以下结构:
Y为:(CH2)n(n等于2,3,4,5,6)等;
R为:上述异羟肟酸1-9各烃基。
本发明所提供的制备式所示化合物的方法,其主要步骤是:由异羟肟酸类RCONHOH(其结构如式II所示)与二元羧酸HOCOYCOOH(其结构如式III所示)于溶媒(有机溶剂或离子液体)中在CDI作用下,于0-200℃反应,制得目标物(式I所示化合物)。
RCONHOH HOCOYCOOR1
II III
式III中,Y的定义与前文所述相同。
在本发明又一个优选的技术方案中,式II所示化合物与式III所示化合物及CDI的摩尔比为2~2.5∶1∶2~5,更优选的技术方案是:式II所示化合物与式III所示化合物的摩尔比为2~2.2∶1∶2~2.5。
在本发明又一个优选的技术方案中,所说的反应介质是有机溶剂或离子液体,如(但不限于):二氯甲烷、三氯甲烷、四氯化碳、甲苯、二甲苯、1,4-二氧六环、N,N-二甲基甲酰胺(DMF)、N,N-二甲基乙酰胺、二甲亚砜(DMSO)、环丁砜、溴化1-丁基-3-甲基咪唑盐([bmim]Br)、1-丁基-3-甲基咪唑四氟硼酸盐([bmim]BF4)或1-丁基-3-甲基咪唑六氟磷酸盐([bmim]PF6)等;
本发明推荐使用的有机溶剂是:二氯甲烷、三氯甲烷和甲苯;
所述有机溶剂的建议用量为10mL~60mL/g·二元羧酸HOCOYCOOH(其结构如式III所示),即:每克二元羧酸HOCOYCOOH(III)需用10mL~60mL所述的有机溶剂。
在本发明所述的制备方法中,可采用薄层层析(TLC)判断制备反应的终点;而所制得的式I所示化合物的粗品,可采用重结晶或柱层析等现有常规的纯化方法进行纯化。
在本发明的又一个具体实施方案中,体外细胞水平抗肿瘤活性研究步骤为:培养人源神经胶质肿瘤细胞U251,将实验药物加入细胞中作用,通过设置不同的药物作用时间和作用浓度,研究实验药物作用的时-效关系和量-效关系;采用MTT法计算生长抑制IC50值,评价实验药物对肿瘤细胞生长抑制作用,采用克隆形成法,计算克隆形成率EC50值,评价药物对肿瘤细胞克隆形成的影响,通过安全系数TI=EC50/IC50计算安全系数值,评价出活性较高的化合物。
异羟肟酸类组蛋白去乙酰化酶抑制剂的二元羧酸双(异羟肟酸)酯衍生物(I)中辛二酸双(N-羟基-N’-苯基辛二酰胺)(YXH-002)和己二酸双(N-羟基-N’-苯基辛二酰胺)(YXH-003)对人结肠癌细胞株HCT116的抑制活性优于伏立诺他。
在本发明的又一个具体实施方案中,异羟肟酸类组蛋白去乙酰化酶抑制剂的二元羧酸双(异羟肟酸)酯衍生物(I)对急性急性髓样白血病(AML);慢性白血病例如慢性淋巴细胞型白血病(CLL)和慢性髓细胞性白血病(CML)、毛细胞性白血病、皮肤T淋巴细胞瘤(CTCL)、非皮肤周围T-细胞淋巴瘤、与嗜人T淋巴细胞病毒(HTLV)相关的淋巴瘤例如成人T细胞性白血病/淋巴瘤(ATLL)、何杰金病、非何杰金淋巴瘤、大细胞淋巴瘤、弥散性大B细胞淋巴瘤(DLBCL);伯基特淋巴瘤;基本的中枢神经系统(CNS)淋巴瘤;多发性骨髓瘤;早期实体瘤例如脑肿瘤、成神经细胞瘤、成视网膜细胞瘤、Wilm’s肿瘤、软组织肉瘤、口腔癌、喉癌、食道癌、前列腺癌、膀胱癌、肾癌、子宫癌、卵巢癌、睾丸癌、直肠癌、结肠癌、肺癌、乳腺癌、胰腺癌、黑素瘤和其它皮肤癌、胃癌、脑肿瘤、肝癌和甲状腺癌有治疗作用。
下面通过实施例对本发明进一步阐述,目的仅在于更好理解本发明的内容。因此,所列实施例并不限制本发明的保护范围:
实施例1丁二酸双(N-羟基-N’-苯基辛二酰胺)(YXH-005)
单口瓶中加入0.118g(1mmol)丁二酸和6ml二氯甲烷,搅拌下分批加入0.324gCDI(2mmol),有气泡产生,室温下继续搅拌25分钟,反应物呈白色浑浊液;然后将0.528g伏立诺他(2mmol)加入反应瓶,TLC检测直至反应结束。将反应液旋干,加入40ml水搅拌10min,有白色固体析出,抽滤,烘干。
mp:177.6-178.4℃;1HNMR(400MHz,d6-DMSO,ppm;见附图中的图1):11.92-11.50(m,1H),9.84(s,1H),7.58(d,J=6.91Hz,2H),7.27(s,2H),7.01(d,J=6.02Hz,1H),2.76(s,4H),2.28(s,2H),2.10(s,2H),1.62-1.46(m,8H),1.29(s,8H);13CNMR(101MHz,d6-DMSO,ppm;见附图中的图2):171.67,170.65,170.19,139.80,129.07,123.36,119.49,36.82,32.27,28.83,28.68,26.52,25.44,25.13。
实施例2己二酸双(N-羟基-N’-苯基辛二酰胺)(YXH-003)
单口瓶加入0.146g(1mmol)己二酸和6ml二氯甲烷,搅拌下分批加入0.324gCDI(2mmol),有气泡产生,室温下搅拌30分钟后将0.528g伏立诺他(2mmol)加入反应瓶,TLC检测直至反应结束。将反应液旋干,加入40ml水搅拌10min,有白色固体析出,抽滤,烘干。
mp:183.6-184.0℃;1HNMR(400MHz,d6-DMSO,ppm;见附图中的图3):11.55(s,1H),9.83(s,2H),7.59(d,J=7.70Hz,4H),7.27(t,J=7.50,7.50Hz,4H),7.01(t,J=7.08,7.08Hz,2H),2.48(d,J=11.21Hz,4H),2.29(t,J=7.08,7.08Hz,4H),2.11(t,J=6.85,6.85Hz,4H),1.65-1.5(m,12H),1.30(s,1H);13CNMR(101MHz,d6-DMSO,ppm,见附图中的图4):171.67,171.49,170.27,139.81,129.07,123.36,119.51,36.84,32.33,31.00,28.84,28.70,28.24,25.45,25.13,24.07。
实施例3辛二酸双(N-羟基-N’-苯基辛二酰胺)(YXH-002)
单口瓶加入0.1742g(1mmol)辛二酸和6ml二氯甲烷,搅拌下分批加入0.324gCDI(2mmol),有气泡产生,室温下搅拌20分钟后将0.528g伏立诺他(2mmol)加入反应瓶,TLC检测直至反应结束。将反应液旋干,加入40ml水搅拌10min,有白色固体析出,抽滤,烘干。
mp:173.1-173.5℃;1HNMR(400MHz,d6-DMSO,ppm;见附图中的图5):9.84(s,1H),7.58(d,J=7.61Hz,2H),7.27(t,J=7.35,7.35Hz,2H),7.00(t,J=6.97,6.97Hz,1H),3.57(s,1H),2.41(t,J=6.64,6.64Hz,2H),2.28(t,J=6.40,6.40Hz,4H),2.10(t,J=6.75,6.75Hz,2H),1.46-1.61(m,8H),1.29(s,1H);13CNMR(101MHz,d6-DMSO,ppm;见附图中的图6):171.67,170.26,139.81,129.07,123.36,119.49,36.83,32.34,31.31,28.83,28.70,28.23,25.45,25.13,24.61。
实施例4癸二酸双(N-羟基-N’-苯基辛二酰胺)(YXH-018)
单口瓶加入0.202g(1mmol)癸二酸和6ml二氯甲烷,搅拌下分批加入0.324gCDI(2mmol),有气泡产生,室温下搅拌35分钟后加入0.528g伏立诺他(2mmol),TLC检测直至反应结束。将反应液旋干,加入40ml水搅拌10min,有白色固体析出,抽滤,烘干。
1H NMR(400MHz,d6-DMSO,ppm;见附图中的图7)11.53(s,1H),9.83(s,1H),7.59(d,J=7.84Hz,1H),7.27(t,J=7.64,7.64Hz,1H),7.01(t,J=7.17,7.17Hz,1H),2.41(t,J=7.02,7.02Hz,1H),2.29(t,J=7.26,7.26Hz,1H),2.11(t,J=7.09,7.09Hz,1H),1.62-1.48(m,12H),1.33-1.23(m,16H);13CNMR(101MHz,d6-DMSO,ppm;见附图中的图8):171.67,170.25,139.81,129.06,123.35,119.49,36.83,32.34,31.39,28.89,28.84,28.70,28.65,25.45,25.13,24.80。
实施例5实验药物对人结肠癌细胞株HCT116的毒性作用
实验药物为合成的二元羧酸双(异羟肟酸)酯衍生物(I),纯度大于99%。用1640培养液稀释成所需浓度。采用噻唑蓝(MTT)快速比色法测定实验药物对HCT116人结肠癌细胞株的毒性作用。将对数生长期细胞(106cell.ml-1)接种于96孔培养板,每孔0.2ml,分别加入一定浓度的实验药物处理,每浓度平行4孔,对照组加等量体积的培养液,置37℃,5%CO2及饱和湿度的培养箱培养48h,实验终止前4小时每孔加入5mg.ml-1MTT 10μl,培养结束后每孔加入0.04N二甲基亚砜(DMSO),每孔150μl,振荡10min,待MTT还原产物完全溶解,用BioRad 550型酶标仪,以550nm为实验波长,655nm为参照波长测定其吸收度,计算肿瘤细胞的抑制率和药物对细胞的抑制率,并以药物的不同浓度和细胞的抑制率作图,确定细胞的半数抑制浓度(IC50)(见附图中的图9)。实验结果如下表1所示。
表一实验药物对人结肠癌细胞株HCT116的细胞毒性
实验药物 | IC50值(μM) |
YXH-002 | 3.56 |
YXH-003 | 2.44 |
YXH-005 | 12.3 |
YXH-018 | 8.10 |
SAHA | 13.6(5.7) |
Claims (5)
1.一类如式I的结构所代表的异羟肟酸类组蛋白去乙酰化酶抑制剂的前药,由式II所示的伏立诺他与式III所示的二元羧酸HOCOYCOOH于有机溶剂或离子液体中在羰基二咪唑作用下,于0-200℃反应制得:
其中,Y代表以下结构:
(CH2)n,其中,n等于2,3,4,5,6;
R基团为
2.根据权利要求1所述的前药,其中,式II所示化合物与式III所示化合物及羰基二咪唑的摩尔比为1.8~2.5∶1∶2~5。
3.根据权利要求1所述的前药,其中,式II所示化合物与式III所示化合物及羰基二咪唑的摩尔比为2~2.2∶1∶2~2.5。
4.根据权利要求1所述的前药,其中,所述的有机溶剂或离子液体包括:二氯甲烷、三氯甲烷、四氯化碳、甲苯、二甲苯、1,4-二氧六环、N,N-二甲基甲酰胺、N,N-二甲基乙酰胺、二甲亚砜、环丁砜、溴化1-丁基-3-甲基咪唑盐、1-丁基-3-甲基咪唑四氟硼酸盐或1-丁基-3-甲基咪唑六氟磷酸盐。
5.根据权利要求1所述的前药,其中,所述有机溶剂的用量为每克二元羧酸使用有机溶剂10mL~60mL。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110357871.5A CN102516124B (zh) | 2011-11-11 | 2011-11-11 | 具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110357871.5A CN102516124B (zh) | 2011-11-11 | 2011-11-11 | 具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102516124A CN102516124A (zh) | 2012-06-27 |
CN102516124B true CN102516124B (zh) | 2015-02-25 |
Family
ID=46287260
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110357871.5A Expired - Fee Related CN102516124B (zh) | 2011-11-11 | 2011-11-11 | 具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102516124B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104854082A (zh) * | 2012-07-20 | 2015-08-19 | 中央研究院 | 3,5,n-三羟基烷酰胺及其衍生物、及其制造方法与用途 |
CN107556349B (zh) * | 2017-10-12 | 2020-11-06 | 杭州医学院 | 一种基于钯碳的伏立诺他衍生物及其制备方法和应用 |
CN108424405A (zh) * | 2018-03-06 | 2018-08-21 | 华东师范大学 | 伏立诺他和紫杉醇的共前药及其制备方法与应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101010298A (zh) * | 2004-04-05 | 2007-08-01 | 默克Hdac研究有限责任公司 | 组蛋白脱乙酰酶抑制剂前药 |
-
2011
- 2011-11-11 CN CN201110357871.5A patent/CN102516124B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101010298A (zh) * | 2004-04-05 | 2007-08-01 | 默克Hdac研究有限责任公司 | 组蛋白脱乙酰酶抑制剂前药 |
Also Published As
Publication number | Publication date |
---|---|
CN102516124A (zh) | 2012-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2378507T3 (es) | Rutas sintéticas para 2(S),4(S),5(S),7(S)-2,7-dialquil-4-hidroxi-5-amino-8-aril-octanoilamidas | |
US20120035255A1 (en) | Derivative of [(3-hydroxy-4 pyron-2-yl)-methyl]-amine and use thereof as anti-neoplastic drugs | |
CN102516124B (zh) | 具有抗肿瘤作用的二元羧酸双(异羟肟酸)酯及制备方法 | |
CN102675153A (zh) | 异羟肟酸的二元羧酸单酯衍生物的抗肿瘤作用和制备方法 | |
CN103554135A (zh) | 一种含色酮结构异噁唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN103554122B (zh) | 一种含色酮结构吡唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN104771392B (zh) | 一类组蛋白去乙酰化酶抑制剂及应用 | |
US8470763B2 (en) | Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereof | |
CN102731493A (zh) | 一类抗肿瘤含苯并噻唑杂环结构的化合物及其应用 | |
Ohno et al. | Synthesis and insecticidal activity of novel 1-alkyl-3-sulfonyloxypyrazole-4-carboxamide derivatives | |
CN104159884B (zh) | 通过使用水或多种酸作为添加剂的新型麦克尔加成反应制备化合物的方法 | |
CN102731529A (zh) | 一种头孢克肟的精制方法 | |
JP6548214B2 (ja) | アミノサリチルアルジミン配位子を金属に配位させた触媒及びこれを用いたヨード環化体の製造方法 | |
CN102531964B (zh) | 具有抗肿瘤作用的二元羧酸衍生物及制备方法 | |
CN108976214B (zh) | 丙酮酸脱氢酶系抑制剂及其制备方法和用途 | |
CN106046028B (zh) | 具有组蛋白去甲基化酶抑制活性天然产物的合成 | |
CN108101892B (zh) | 一种白杨素非天然氨基酸衍生物及其制备方法和应用 | |
Zhang et al. | Synthesis, anticancer evaluation and docking study of vadimezan derivatives with carboxyl substitution | |
CN102617546A (zh) | 还原型烟酰胺腺嘌呤二核苷酸氧化酶抑制剂芳香碘鎓盐及其抗肿瘤应用 | |
CN105061267A (zh) | 蓓萨罗丁的no供体n-羟基胍类衍生物及其制备方法 | |
EP3105242A1 (en) | 2',5'-dideoxy-5-fluorouridine derivatives having cytotoxic activity, a process for the manufacture thereof and application thereof | |
CN103965104A (zh) | 一种酪氨酸激酶抑制剂及其中间体的制备方法 | |
CN103554134B (zh) | 含色酮结构异噁唑类去甲斑蝥素衍生物及其制备方法与应用 | |
CN107810961A (zh) | Topsentin类生物碱在抗植物病毒和病菌中的应用 | |
JP2012240959A (ja) | 光学活性β−アミノチオールまたは光学活性β−アミノスルホン酸誘導体の合成法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150225 |